Licensing
GSK set to receive over $500M from mRNA patent settlement tied to BioNTech–CureVac–Pfizer deal
GSK; CureVac; BioNTech; Pfizer; mRNA patents; settlement; royalties; COVID-19 vaccine; influenza vaccine; combination vaccines; licensing; upfront payment; US litigation; global framework; BioNTech acquisition of CureVac
GSK Strengthens COPD Offering via $12 Billion Multi-Program Deal with China’s Hengrui Pharma
GSK; Hengrui Pharma; COPD; biobucks; PDE3/4 inhibitor; HRS-9821; Nucala; immunology; oncology; licensing deal
Alphabet’s Calico Strikes $596M Deal for Mabwell’s Anti-Aging Antibody
Calico; Alphabet; Mabwell; anti-aging; biotech; IL-11 antibody; 9MW3811; exclusive licensing; aging-related diseases; biopharma deal
InnoCare and KeyMed Secure $520M Licensing Deal for Bispecific Antibody with RTW-Built Biotech
InnoCare, KeyMed, Bispecific Antibody, RTW Investments, Licensing Deal, $520M
Galapagos Partners with Adaptimmune for $665M T-Cell Therapy Collaboration
Galapagos, Adaptimmune, T-cell therapy, MAGE-A4 TCR, Uza-cel, Biobucks collaboration, Licensing deal, Financing, Next-generation therapy
Erasca Pivots Strategy, Secures $160M and Licenses Chinese Cancer Drugs Amidst Workforce Restructuring
Erasca, pipeline, workforce reduction, licensing, cancer drugs, China, $160M, strategic shift